2-(4-Chlor-benzylamino)-benzamid | 20287-39-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Chlor-benzylamino)-benzamid
• 英文别名: o-(4-Chlorbenzylamino)-benzamid；2-[(4-Chlorobenzyl)amino]benzenecarboxamide；2-[(4-chlorophenyl)methylamino]benzamide
• CAS: 20287-39-2
• 化学式: C₁₄H₁₃ClN₂O
• 分子量: 260.723
• InChiKey: HMOMYOFFTWHHAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-Chlor-benzylamino)-benzamid 在 碘 、 二甲基亚砜 作用下， 反应 6.0h， 以85%的产率得到2-(4-chlorophenyl)-4(3H)-quinazolinone
  参考文献：
  名称：

  Access to 2‐Arylquinazolin‐4(3H)‐ones through Intramolecular Oxidative C(sp ³ )−H/N−H Cross‐Coupling Mediated by I ₂ /DMSO

  摘要：

  AbstractA novel approach for the synthesis of 2‐arylquinazolin‐4(3H)‐ones was developed. A series of title compounds were obtained with good functional group tolerance and good yields by I2/DMSO‐mediated intramolecular oxidative cross‐coupling of 2‐(benzylamino)benzamides to form C=N double bonds. This method was applicable for gram‐scale synthesis. A proposed reaction pathway based on some control experiments was also provided.

  DOI：

  10.1002/ejoc.202101187
• 作为产物：
  描述：

  4(1H)-喹唑啉酮,2-(4-氯苯基)-2,3-二氢- 在 硼烷-三甲胺络合物 作用下， 以 溶剂黄146 为溶剂， 生成 2-(4-Chlor-benzylamino)-benzamid
  参考文献：
  名称：

  Biressi; Cantarelli; Carissimi, Farmaco, Edizione Scientifica, 1969, vol. 24, # 2, p. 199 - 220

  摘要：

  DOI：

文献信息

• Naryl-substituted anthranilamides with intramolecular hydrogen bonds
  作者：Li-Xia Wang、Ben-Quan Hu、Jun-Feng Xiang、Jie Cui、Xiang Hao、Tong-Ling Liang、Ya-Lin Tang

  DOI：10.1016/j.tet.2014.09.057

  日期：2014.11

  plays an important role in forming the presence of intramolecular hydrogen bonds. The chemical shift of the Naryl-H downfield changes obviously, due to the formation of intramolecular hydrogen bonds and the deshielding effect of oxygen, and the neighboring C–H is activated and shows downfield protonic signal too. The presence of intramolecular hydrogen bonds probably provides the explanation for the transformation

  氢键相互作用作为一种非共价力已被证明对构建结构独特的人工二级结构非常有效。在此，通过各种NMR技术对溶液中的N芳基取代的邻氨基苯甲酰胺的结构进行了说明，提出了与相同环的芳胺连接的酰胺之间的分子内氢键，并通过固相的晶体结构来支持。芳基胺的氮原子上的取代基在形成分子内氢键的存在中起重要作用。N芳基的化学位移由于分子内氢键的形成和氧的去屏蔽作用，-H下场发生了明显变化，相邻的C–H也被激活并显示出下场质子信号。分子内氢键的存在可能为N芳基取代的邻氨基苯甲酰胺向亚胺的转化提供了解释，后者最终可以转化为2-芳基喹唑啉酮。
• Quinazoline-3-alkanoic acid derivatives, their salts and their
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US05234928A1

  公开（公告）日：1993-08-10

  The present invention relates to quinazoline-3-alkanoic acid derivatives having both an inhibitory effect on platelet aggregation and a hindering effect on aldose reductase together, represented by a general formula [I] ##STR1## [wherein R is hydrogen or a protecting group for carboxyl group, R.sup.1 is a lower alkyl group, alkenyl group, alkinyl group, lower alkoxy group, lower alkylthio group, halogen, phenyl group (this phenyl group may be substituted by one to three of lower alkyls, lower alkoxys, halogens, trifluoromethyls, carboxyethylenes or ethoxycarbonylethylenes, naphthyl group, heterocycle (this heterocycle may be substituted by one to three of lower alkyls), cycloalkyl group or benzoyl group (this benzoyl group may be substituted by lower alkyl or halogen), R.sup.2 and R.sup.3 are identically or differently hydrogens, halogens, lower alkyl groups, lower alkoxy groups, aralkyl groups which may be substituted, nitro groups, imidazolyl groups, imidazolylmethyl groups or ##STR2## (R.sup.4 and R.sup.5 indicate identically or differently hydrogens or lower alkyl groups, or connected with each other to make five- or six-membered heterocycles which may contain other hetero atom, X is carbonyl, thiocarbonyl or methylene group (this methylene group may be substituted by lower alkyl group), A is lower alkylene or lower alkenylene, and n indicates an integer of 1 to 3], their salts, their preparation processes and medicinal drugs containing them.

  本发明涉及一种具有抑制血小板聚集和阻碍醛固酮还原酶的效果的喹嗪-3-烷酸衍生物，其由通式[I]表示：##STR1## [其中R为氢或羧基的保护基，R1为较低的烷基、烯基、炔基、较低的烷氧基、较低的烷基硫基、卤素、苯基（该苯基可以被一个到三个较低的烷基、较低的烷氧基、卤素、三氟甲基、羧乙烯或乙氧羰基乙烯替代），萘基、杂环（该杂环可以被一个到三个较低的烷基替代）、环烷基或苯甲酰基（该苯甲酰基可以被较低的烷基或卤素替代），R2和R3均为氢、卤素、较低的烷基、较低的烷氧基、可能被取代的芳基烷基、硝基、咪唑基、咪唑基甲基或##STR2##（R4和R5表示相同或不同的氢或较低的烷基，或连接起来形成五元或六元杂环，可以含有其他杂原子，X为羰基、硫代羰基或亚甲基基（该亚甲基基可以被较低的烷基替代），A为较低的烷基或较低的烯基，n为1到3的整数]，它们的盐、制备过程和含有它们的药物。
• QUINAZOLINE-3-ALKANOIC ACID DERIVATIVE, SALT THEREOF, AND PRODUCTION THEREOF
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：EP0456835A1

  公开（公告）日：1991-11-21

  A quinazoline-3-alkanoic acid derivative of general formula (I), which has both of platelet agglutination inhibition and aldose reductase inhibition activities, salts thereof, process for producing the same, and a medicine containing the same, wherein R represents hydrogen or a protective group of the carboxyl group; R' represents lower alkyl, alkenyl, alkynyl, lower alkoxy, lower alkylthio, halogen, phenyl (which may be substituted with 1 to 3 substituents selected from among lower alkyl, lower alkoxy, halogen, trifluoromethyl, carboxyethylene, and ethoxy-carbonylethylene groups), naphthyl, heterocycle (which may be substituted with 1 to 3 lower alkyl groups), cycloalkyl, or benzoyl (which may be substituted with lower alkyl or halogen); R² and R³ may be the same or different from each other and each represents hydrogen, halogen, lower alkyl, lower alkoxy, optionally substituted aralkyl, nitro, imidazolyl, imidazolylmethyl, or -NR⁴R⁵ wherein R⁴ and R⁵ may be the same or different from each other and each represents hydrogen or lower alkyl, or they are combined with each other to form a 5- or 6-membered heterocycle which may contain other heteroatom(s); X represents carbonyl, thiocarbonyl or methylene (which may be substituted with lower alkyl); A represents lower alkylene or lower alkenylene; and n is an integer of 1 to 3.

  一种同时具有血小板凝集抑制活性和醛糖还原酶抑制活性的通式(I)的喹唑啉-3-烷酸衍生物、其盐类、生产工艺以及含有该衍生物的药物，其中 R 代表氢或羧基的保护基团；R'代表低级烷基、烯基、炔基、低级烷氧基、低级烷硫基、卤素、苯基（可被 1 至 3 个选自低级烷基、低级烷氧基、卤素、三氟甲基、羧基乙烯和乙氧基羰基乙烯基团的取代基取代）、萘基、杂环（可被 1 至 3 个低级烷基取代）、环烷基或苯甲酰基（可被低级烷基或卤素取代）；R² 和 R³ 可以相同或互不相同，各自代表氢、卤素、低级烷基、低级烷氧基、任选取代的芳烷基、硝基、咪唑基、咪唑甲基或 -NR⁴R⁵，其中 R⁴ 和 R⁵ 可以相同或互不相同，各自代表氢或低级烷基，或者它们相互结合形成 5 或 6 元杂环，该杂环可含有其他杂原子；X 代表羰基、硫代羰基或亚甲基（可被低级烷基取代）；A 代表低级亚烷基或低级亚烯基；n 是 1 至 3 的整数。
• US5234928A
  申请人：——

  公开号：US5234928A

  公开（公告）日：1993-08-10
• Biressi; Cantarelli; Carissimi, Farmaco, Edizione Scientifica, 1969, vol. 24, # 2, p. 199 - 220
  作者：Biressi、Cantarelli、Carissimi、Cattaneo、Ravenna

  DOI：——

  日期：——